Announcements
- 2025.12.12 (1) PROPOSED ABOLISHMENT OF THE BOARD OF SUPERVISORS; (2) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION; (3) PROPOSED AMENDMENTS TO THE RULES OF PROCEDURE FOR SHAREHOLDERS' MEETINGS; (4) PROPOSED AMENDMENTS TO THE RULES OF PROCEDURE FOR THE BOARD OF DIRECTORS; AND (5) NOTICE OF THE 2025 THIRD EXTRAORDINARY GENERAL MEETING
- 2025.12.12 (1) PROPOSED ABOLISHMENT OF THE BOARD OF SUPERVISORS; (2) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION; (3) PROPOSED AMENDMENTS TO THE RULES OF PROCEDURE FOR SHAREHOLDERS' MEETINGS; (4) PROPOSED AMENDMENTS TO THE RULES OF PROCEDURE FOR THE BOARD OF DIRECTORS
- 2025.12.08 ANNOUNCEMENT - BOOK CLOSURE PERIOD FOR THE 2025 THIRD EXTRAORDINARY GENERAL MEETING
- 2025.12.04 Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2025
- 2025.11.20 VOLUNTARY ANNOUNCEMENT THE SIX-MONTH CLINICAL FOLLOW-UP RESULTS FOR LARGE ANNULUS PATIENTS OF LUX-VALVE PLUS TRINITY STUDY AND CLINICAL APPLICATION RESULTS FOR LARGE ANNULUS PATIENTS OF KEN-VALVE RELEASED AT PCR LONDON VALVES 2025, DEMONSTRATING LARGE SIZE ADVANTAGES WITH PRODUCT UNIQUENESS
- 2025.11.06 Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2025
- 2025.10.31 CLARIFICATION ANNOUNCEMENT
- 2025.10.29 VOLUNTARY ANNOUNCEMENT UPDATE ON RESULTS OF CLINICAL STUDIES OF THE COMPANY'S MULTI-PRODUCT PORTFOLIO ARE RELEASED AT TCT 2025 IN THE U.S., INCLUDING THE LUX-VALVE PLUS TRINITY STUDY, JENSCLIP CLINICAL STUDY, AND KEN-VALVE CLINICAL STUDY
- 2025.10.28 VOLUNTARY ANNOUNCEMENT REMARKABLE RESULTS OF CLINICAL STUDIES OF THE COMPANY'S MULTI-PRODUCT PORTFOLIO ARE RELEASED AT TCT 2025 IN THE U.S., INCLUDING THE LUX-VALVE PLUS TRINITY STUDY, JENSCLIP CLINICAL STUDY, AND KEN-VALVE CLINICAL STUDY
- 2025.10.15 POLL RESULTS OF THE 2025 SECOND EXTRAORDINARY GENERAL MEETING
Privacy Law Copyright © Jenscare Scientific Co., Ltd. All rights reserved. 网站备案/许可证号：浙ICP备17016094号
